NCT00894114View on ClinicalTrials.gov

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

PHASE1CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

V520

MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection

BIOLOGICAL

Comparator: ALVAC-HIV vaccine

A single dose 0.1 intramuscular injection

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00894114 - A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) | Biotech Hunter | Biotech Hunter